Traws Pharma Inc - Company Profile
Powered by 
All the data and insights you need on Traws Pharma Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Traws Pharma Inc Strategy Report
- Understand Traws Pharma Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Onconova Therapeutics Inc (Onconova) is a biopharmaceutical company that discovers and develops small molecule drug candidates for the treatment of cancer. The company’s drug candidates include rigosertib and ON123300. It develops drug candidates that target cancer and protect healthy cells based on its proprietary chemistry platform and cell-based differential screening. Onconova’s rigosertib is targeted at meeting the medical needs of patients with myelodysplastic syndromes. The company’s recilisib is used to treat the effects of acute radiation syndromes such as cytopenia. It partnered with biopharmaceutical companies and medical organizations in the US. Onconova is headquartered in Newtown, Pennsylvania, the US.
Headquarters
United States of America
Address
12 Penns Trail, Newtown, Pennsylvania, 18940
Website
www.onconova.com
Telephone
1 267 7593680
No of Employees
16
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TRAW (NASD)
Revenue (2022)
$226,000
EPS
XYZ
Net Income (2022)
XYZ
0.1%
(2022 vs 2021)
Market Cap*
$16.7M
Net Profit Margin (2022)
XYZ
0.1%
(2022 vs 2021)
* As of and is in US$
Traws Pharma Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Narazaciclib (ON 123300) - Solid Tumors |
| Oral Rigosertib - KRAS+ NSCLC |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Acquisitions/Mergers/Takeovers | In April, the company acquired Trawsfynydd Therapeutics, Inc., a biotechnology firm. |
| 2023 | Contracts/Agreements | In March, the company initiated a research collaboration with Pangea Biomed with the objective of identifying biomarkers that can predict the response to Rigosertib. |
| 2019 | Contracts/Agreements | In December, the company and Inceptua entered into a collaboration to make available intravenous rigosertib via a pre-approval access program. |
Competitor Comparison
| Key Parameters | Traws Pharma Inc | Baxter International Inc | Acceleron Pharma Inc | MEI Pharma Inc | Five Prime Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Newtown | Deerfield | Cambridge | San Diego | South San Francisco |
| State/Province | Pennsylvania | Illinois | Massachusetts | California | California |
| No. of Employees | 16 | 60,000 | 312 | 46 | - |
| Entity Type | Public | Public | Private | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| James J. Marino | Chairman | Executive Board | 2020 | 73 |
| Steven M. Fruchtman | Chief Executive Officer; Director; President | Executive Board | 2019 | 72 |
| Mark P. Guerin | Chief Financial Officer; Chief Operating Officer | Senior Management | 2022 | 54 |
| Victor Moyo | Chief Medical Officer | Senior Management | 2023 | - |
| Matthew Parris | Vice President - Clinical Operations | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer